Trial reportThe Journal of urology2012
Evaluation of vitamin E and selenium supplementation for the prevention of bladder cancer in SWOG coordinated SELECT.
Trial report in The Journal of urology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 4 syntheses or guidelines pooled it, 47 citations in OpenAlex.
- Selenium for preventing cancer.The Cochrane database of systematic reviews · 2018Pooled it
- Effects of Vitamin and Antioxidant Supplements in Prevention of Bladder Cancer: a Meta-Analysis of Randomized Controlled Trials.Journal of Korean medical science · 2017Pooled it
- Selenium Exposure and Cancer Risk: an Updated Meta-analysis and Meta-regression.Scientific reports · 2016Pooled it
- Selenium for preventing cancer.The Cochrane database of systematic reviews · 2014Pooled it
- Selenium and Vitamin E for Prevention of Non-Muscle-Invasive Bladder Cancer Recurrence and Progression: A Randomized Clinical Trial.JAMA network open · 2023Trial
- Selenium compounds for cancer prevention and therapy - human clinical trial considerations.Medical review (2021) · 2025Review
- Supplementary selenium and vitamin E in non-muscle-invasive bladder cancer.Nature reviews. Urology · 2024Article
- Selenium and Selenoproteins in Health.Biomolecules · 2023Review
- Current and Emerging Treatments for Urothelial Carcinoma: A Focus on Enfortumab Vedotin.Cancer management and research · 2023Review
- Association of metabolic syndrome and the risk of bladder cancer: A prospective cohort study.Frontiers in oncology · 2022Article
- Vitamin E and cancer prevention: Studies with different forms of tocopherols and tocotrienols.Molecular carcinogenesis · 2020Review
- Epidemiology of Bladder Cancer.Medical sciences (Basel, Switzerland) · 2020Review
- Environmental Selenium and Human Health: an Update.Current environmental health reports · 2018Review
- Low-Grade, Multiple, Ta Non-muscle-Invasive Bladder Tumors: Tumor Recurrence and Worsening Progression.Indian journal of surgical oncology · 2018Article
- Sulforaphane for the chemoprevention of bladder cancer: molecular mechanism targeted approach.Oncotarget · 2017Review
- Health risk assessment of environmental selenium: Emerging evidence and challenges (Review).Molecular medicine reports · 2017Review
- Oxidative stress in prostate cancer patients: A systematic review of case control studies.Prostate international · 2016Review
- Tocopherols in cancer: An update.Molecular nutrition & food research · 2016Review
- The role of micronutrients in the risk of urinary tract cancer.Archives of medical science : AMS · 2016Article
- Selenite-induced autophagy antagonizes apoptosis in colorectal cancer cells in vitro and in vivo.Oncology reports · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 1 country.
Funding
Abstract
purposeEpidemiological and biological evidence suggests a preventive effect of selenium and vitamin E on bladder cancer. We assessed the effect of selenium and/or vitamin E on bladder cancer development. MATERIALS AND
methodsThis was a secondary analysis of the randomized, placebo controlled SELECT (Selenium and Vitamin E Cancer Prevention Trial), which included 34,887 men randomly assigned to 4 groups (selenium, vitamin E, selenium plus vitamin E and placebo) in double-blind fashion between August 22, 2001 and June 24, 2004. The primary end point was bladder cancer incidence, as determined by routine clinical management.
resultsDuring a median followup of 7.1 years (IQR 6.4-8.0) 224 bladder cancer cases were recorded. Patients with bladder cancer were older, and more likely to be white and have a smoking history than those without bladder cancer. Most cancers were urothelial and nonmuscle invasive. There was no significant difference in the bladder cancer incidence between the 53 men in the placebo group and the 56 in the vitamin E group (HR 1.05, IQR 0.64-1.73, p=0.79), the 60 in the selenium group (HR 1.13, 0.70-1.84, p=0.52) or the 55 in the vitamin E plus selenium group (HR 1.05, 0.63-1.70, p=0.86).
conclusionsThis secondary analysis showed no preventive effect of selenium or vitamin E alone or combined on bladder cancer in this population of men. Further studies are needed to assess the effect in women, and at different doses and formulations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.